SARS-CoV-2 Blocks Innate Immune Activation to Cause COVID-19 Infection, Study Suggests
By HospiMedica International staff writers Posted on 26 Jan 2021 |
Illustration
A new study has revealed that the SARS-CoV-2 virus replicates and spreads in the body unchecked by suppressing innate immunity, leading to the disease known as COVID-19.
A recent review article in Journal of Interferon & Cytokine Research (JICR) by researchers at the University of Texas Medical Branch at Galveston (Galveston, TX, USA) has summarized that SARS-CoV-2 blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues. IFN-I is a key component of host innate immunity that is responsible for eliminating the virus at the early stage of infection. By suppressing innate immunity, the virus replicates and spreads in the body unchecked, leading to COVID-19.
"SARS-CoV-2 utilizes various approaches to evade host IFN-I response, including suppression of IFN-I production and IFN-I signaling," said Hongjie Xia and Pei-Yong Shi, University of Texas Medical Branch at Galveston. "Viruses defective in antagonizing IFN-I response, in combination with replication-defective mutations, could potentially be developed as live attenuated vaccine candidates."
"Targeting innate immunity is highly attractive for therapeutic and vaccine strategies aimed at controlling SARS-CoV-2 infection and protecting against COVID-19. By revealing how the virus blocks innate immune programs we can then build approaches to restore these processes and enhance antiviral immunity," added Journal of Interferon & Cytokine Research Editor-in-Chief Michael Gale Jr., Department of Immunology and Center for Innate Immunity and Immune Disease, University of Washington.
Related Links:
University of Texas Medical Branch at Galveston
A recent review article in Journal of Interferon & Cytokine Research (JICR) by researchers at the University of Texas Medical Branch at Galveston (Galveston, TX, USA) has summarized that SARS-CoV-2 blocks the processes of innate immune activation that normally direct the production and/or signaling of type I interferon (IFN-I) by the infected cell and tissues. IFN-I is a key component of host innate immunity that is responsible for eliminating the virus at the early stage of infection. By suppressing innate immunity, the virus replicates and spreads in the body unchecked, leading to COVID-19.
"SARS-CoV-2 utilizes various approaches to evade host IFN-I response, including suppression of IFN-I production and IFN-I signaling," said Hongjie Xia and Pei-Yong Shi, University of Texas Medical Branch at Galveston. "Viruses defective in antagonizing IFN-I response, in combination with replication-defective mutations, could potentially be developed as live attenuated vaccine candidates."
"Targeting innate immunity is highly attractive for therapeutic and vaccine strategies aimed at controlling SARS-CoV-2 infection and protecting against COVID-19. By revealing how the virus blocks innate immune programs we can then build approaches to restore these processes and enhance antiviral immunity," added Journal of Interferon & Cytokine Research Editor-in-Chief Michael Gale Jr., Department of Immunology and Center for Innate Immunity and Immune Disease, University of Washington.
Related Links:
University of Texas Medical Branch at Galveston
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans